Wall Street brokerages forecast that Mesoblast limited (NASDAQ:MESO) will announce ($0.24) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Mesoblast’s earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.25). Mesoblast reported earnings of ($0.08) per share during the same quarter last year, which suggests a negative year over year growth rate of 200%. The firm is expected to report its next quarterly earnings results on Tuesday, November 13th.
According to Zacks, analysts expect that Mesoblast will report full-year earnings of ($1.01) per share for the current fiscal year, with EPS estimates ranging from ($1.12) to ($0.95). For the next financial year, analysts forecast that the business will post earnings of ($0.81) per share, with EPS estimates ranging from ($1.09) to ($0.53). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Mesoblast.
Mesoblast (NASDAQ:MESO) last issued its earnings results on Wednesday, August 29th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.01. Mesoblast had a negative net margin of 203.51% and a negative return on equity of 10.48%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $2.51 million.
MESO stock traded down $0.71 on Friday, hitting $7.39. The company had a trading volume of 65,327 shares, compared to its average volume of 46,662. Mesoblast has a 12-month low of $4.74 and a 12-month high of $8.78. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $713.82 million, a P/E ratio of -11.73 and a beta of 1.96.
A hedge fund recently bought a new stake in Mesoblast stock. Jane Street Group LLC purchased a new position in shares of Mesoblast limited (NASDAQ:MESO) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 17,731 shares of the company’s stock, valued at approximately $102,000. Hedge funds and other institutional investors own 2.74% of the company’s stock.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Featured Story: Short Selling Stocks, A Beginner’s Guide
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.